Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 89.64 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.82 -3.52 -3.07 -2.64 -3.92 -5.39 -7.27 -7.4 Dividends USD Payout Ratio % * Shares Mil 13.0 13.0 18.0 27.0 38.0 44.0 48.0 50.0 Book Value Per Share * EUR 5.35 2.79 6.56 9.72 9.37 11.38 Free Cash Flow Per Share * EUR -1.08 -0.87 -2.61 -3.37 -5.98 Return on Assets % -575.14 -170.37 -48.88 -31.4 -29.67 -37.69 -55.73 -50.91 Financial Leverage (Average) 1.24 1.33 1.15 1.29 1.52 1.34 Return on Equity % -173.14 -40.61 -35.39 -45.38 -78.72 -72.29 Return on Invested Capital % -130.06 -38.33 -34.3 -43.99 -69.96 -60.78 Interest Coverage -150.54 -87.93 -74.82 -153.57 -669.22 Current Ratio 0.78 7.14 9.14 7.73 15.98 8.29 4.85 7.17 Quick Ratio 0.63 6.98 8.91 7.64 15.7 8.19 4.76 7.04 Debt/Equity 0.05 0.02 0.02 0.03 0.19 0.13